[27] Pagliuca S, Risitano A, De Fontbrune F, 2018. Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. Bone Marrow Transplan.;53(1):105-107.

[28]. Marsh J, Schrezenmeier H, Marin P, 1999. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT). Blood.;93(7):2191-2196.

[29] Advani, R.H., Horning, S.J., Hoppe, R.T., Daadi, S., Allen, J., Natkunam, Y. & Bartlett, N.L. 2014. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Journal of Clinical Oncology, 32, 912–918.

 [30] Ali, H., Naresh, K. & Aqel, N.M. 2013. Primary nodular lymphocyte predominant Hodgkin lymphoma of the palate: a rare incidence which was also associated with progressive transformation of germinal centres of cervical lymph node. Journal of the Egyptian National Cancer Institute, 25, 161–163.

[31] Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, 2007. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood.;109(8):3219-24.

[32] Vallejo C, Montesinos P, Rosell A, Brunet S, Raul Córdoba, Elena Pérez-Ceballos. 2009. Comparison between lymphoglobuline- and thymoglobuline-based immunosuppressive

therapy as first-line treatment for patients with aplastic anemia. Blood;114(22):3194a.